ACTRN12614000126617进行中（未招募）3 期
A randomised study of male participants with localised prostate cancer at high risk for recurrence deemed suitable for external beam radiation therapy with a luteinising releasing hormone releasing hormone analogue (LHRHA) treatment combined with the commencement of either 160mg daily Enzalutamide or conventional Non-steroidal anti-androgen (NSAA) to determine the effects of overall survival
HMRC Clinical Trials Centre (CTC) , University of Sydney0 个研究点目标入组 802 人开始时间: 2014年2月3日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 802
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Male
入选标准
- •1) Pathological diagnosis of adenocarcinoma of the prostate, judged to be at high risk for recurrence based on any of the following (in accordance with the ISUP Consensus 2005: a) Gleason score 8-10 OR b) Gleason score of 4+3 AND clinical T2b-4 AND PSA >20nj/mL OR c) N1 disease (involvement of lymph nodes at or below the bifurcation of the common iliac arteries) defined radiologically as greater than 10mm on short axis using standard CT or MRI, or biopsy proven
- •2) Age >=18 yrs
- •3) Adequate bone marrow function
- •4) Adequate liver function
- •5) Adequate renal function
- •6) ECOG performance status of 0-1
- •7) Study treatment both planned and able to start within 7 days of randomisation.
- •8) Willing and able to comply with all study requirements, including treatment, and attending required assessments
- •9) Has completed the baseline HRQOL questionnaires UNLESS is unable to complete because of literacy or limited vision
- •10) Signed, written, informed consent
排除标准
- •1) Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small cell components
- •2) Involvement of lymph nodes superior to the common iliac bifurcation, and/or outside the pelvis (distant lymph nodes). Lymph node involvement is defined by histopathological confirmation, or by a short axis measurement >10mm on standard imaging (CT or MRI, but not PET).
- •3) Any contraindication to external beam radiotherapy
- •4) History of a) seizure or any condition that may predispose to seizure (e.g., prior cortical stroke or significant brain trauma). b) loss of consciousness or transient ischemic attack within 12 months of randomization c) significant cardiovascular disease within the last 3 months: including myocardial infarction, unstable angina, congestive heart failure (NYHA grade II or greater), ongoing arrhythmias of Grade > 2 (NCI CTCAE, version 4.03) , thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism). Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed.
- •5) Evidence of metastatic disease: minimum imaging required CT / MRI and WBBS. If equivocal bone scan, follow-up plain films are required to show NO evidence of cancer if not covered by CT/MRI
- •6) PSA > 100 ng/mL
- •7) History of another malignancy within 5 years prior to randomisation except for non-melanomatous carcinoma of the skin; or, adequately treated, non-muscle-invasive urothelial carcinoma of the bladder (i.e. Tis, Ta and low grade T1 tumours).
- •8) Concurrent illness, including severe infection that might jeopardize the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety a) HIV-infection is not an exclusion criterion if it is controlled with anti-retroviral drugs that are unaffected by concomitant enzalutamide.
- •9) Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse;
- •10) Patients who are sexually active and not willing/able to use medically acceptable forms of barrier contraception.
- •11) Use of hormonal therapy or androgen deprivation therapy, including enzalutamide, except in the following setting: a) Use of LHRHA (with or without anti-androgens) for less than 30 days prior to randomisation in the trial.
- •12) Bilateral orchidectomy or radical prostatectomy
- •13) Prior brachytherapy or other radiotherapy that would result in an overlap of radiotherapy fields
- •14) Participation in other clinical trials of investigational agents for the treatment of prostate cancer or other diseases.
- •15) Major surgery within 21 days prior to randomisation
- •16) Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of enzalutamide, including difficulty swallowing tablets
研究者
相似试验
进行中（未招募）
3 期
Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMETProstate CancerACTRN12614000110684HMRC Clinical Trials Centre (CTC), University of Sydney1,125
尚未招募
不适用
18-Fluoride (18F) labelled Sodium Fluoride (NaF)) Positron Emission Tomography (PET)/Computer Tomography (CT); the impact on pre-operative staging of intermediate and high risk prostate cancerCancer - ProstateProstate CancerACTRN12614000877684Dr. Simon Harley20
已完成
1 期
A phase I study to determine the tolerability and safety of transdermally delivered oxycodone in combination with the novel penetration enhancer tocopheryl phosphate mix (TPM).To promote pain relief in healthy volunteers.Anaesthesiology - Pain managementACTRN12609000836235Phosphagenics Limited44
招募中
不适用
A prospective randomized study on the incidence of postoperative Proximal junctional fracture(PJF) in patients undergoing spinal deformity surgery according to osteoporosis drugsAdult spinal deformity surgeryJPRN-UMIN000044337Hamamatsu University School of Medicine60
已完成
不适用
Prospective randomised study of the influence of a lung recruitment strategy on oxygenation in the post-anaesthetic care unit (PACU)ISRCTN32464251Record Provided by the NHSTCT Register - 2006 Update - Department of Health44